Skip to main
NKTX
NKTX logo

Nkarta, Inc. (NKTX) Stock Forecast & Price Target

Nkarta, Inc. (NKTX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nkarta Inc. is positioned favorably in the biopharmaceutical landscape due to its innovative approach in developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies, which provide a promising alternative to existing CAR-T therapies. The company's recent decision to standardize lymphodepletion with fludarabine has notably enhanced patient enrollment, a crucial factor in advancing its clinical trials and pipeline. Additionally, the investment potential in Nkarta is underscored by its attractive valuation and the anticipated growth in engineered cell-based therapies, as the market increasingly recognizes the advantages of leveraging NK cells for cancer treatment.

Bears say

Nkarta Inc's financial outlook appears negative due to a significant decline in both research and development (R&D) and selling, general, and administrative (SG&A) expenditures, with R&D spending down 14% sequentially and SG&A spending down 48%. Additionally, the company faces potential constraints related to the protocol amendment anticipated in May 2025, which may hinder the ability to draw definitive conclusions from initial findings due to a limited patient sample representing a spectrum of different autoimmune diseases (AIDs). The overall financial health, characterized by reduced spending in critical areas, coupled with uncertainties in clinical outcomes, raises concerns about Nkarta’s ability to successfully advance its NK cell therapy programs.

Nkarta, Inc. (NKTX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nkarta, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nkarta, Inc. (NKTX) Forecast

Analysts have given Nkarta, Inc. (NKTX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Nkarta, Inc. (NKTX) has a Strong Buy consensus rating as of Oct 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nkarta, Inc. (NKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.